AACR 2021 | Validation of FAPi PET biodistribution

Jeremie Calais • 22 Apr 2021

AACR 2021

Jeremie Calais, MD, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, outlines the validation of fibroblast activated protein (FAP) PET biodistribution at AACR 2021. A prospective, exploratory study of patients who were scheduled to undergo surgical resection of the primary tumor investigated the incidence and degree of FAP expression by immunohistochemistry and explored whether gallium-68 FAPi-46 PET imaging accurately reflects tumor FAP expression from resected tumor and non-tumor specimens. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.

Disclosures

Jeremie Calais, MD, has received honoraria from Advanced Accelerator Applications, Blue Earth Diagnostics, Curium Pharma, GE Healthcare, IBA RadioPharma, Janssen Pharmaceuticals, POINT biopharma, Progenics/Lantheus, Radiomedix and Telix Pharmaceuticals; has participated in consultancy work with Blue Earth Diagnostics, Curium Pharma, GE Healthcare, Janssen Pharmaceuticals, POINT biopharma and Progenics/Lantheus; has participated in a speaker role for IBA RadioPharma and Telix Pharmaceuticals; has acted as a blinded independent central reader for Advanced Accelerator Applications, Progenics/Lantheus and Radiomedix, and has received research support from Progenics/Lantheus.